Former Medicine Development Leader for MAGE-A4+ Autologous Cell Therapies Will Support Advancement of CDR-Life’s M-gager® Solid Tumor TherapiesZÜRICH, Switzerland, Aug....
Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in...
JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer...
MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry...
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with...
Provista begins validation preparations for blood-based IgM/IgG MonkeyPox LDTCompany to release its Q2/2022 10Q quarterly report at 4:05 pm ET...
New York, NY, and Tel Aviv, ISRAEL, Aug. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive...
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL),...
Dr. Richard Caruso Dr. Richard Caruso, founder and former Chairman and CEO of Integra LifeSciencesPRINCETON, N.J., Aug. 16, 2022 (GLOBE...
LA JOLLA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Two-Year, In-Depth Analysis Suggests Ovia’s Platform Can Also Reduce Maternity Claims CostsBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- A digital...
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an...
Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data...
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including...
-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of...
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312...